Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000287559 is a non-coding RNA “novel transcript” found antisense to the RNA binding motif protein 24 (RBM24) gene. Its biological function has not been characterized, and there is no evidence it is a direct target for drugs or known to be involved in disease. In contrast, RBM24 itself is a protein-coding gene encoding an RNA binding protein important for tissue-specific alternative splicing in heart and muscle development, apoptosis regulation, fibrosis, and hearing functions[3][1][4]. The antisense transcript may influence RBM24 gene expression through regulatory RNA interactions, but such activity is not established in current research. Key distinction: If your intent is to describe a structured, actionable target (e.g., therapeutic, receptor, or disease biomarker), RBM24 (RNA binding motif protein 24) is the canonical protein-coding gene and should be considered, not "novel transcript, antisense to RBM24" (ENSG00000287559), which currently lacks functional annotation and documented biomedical relevance as a target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RNA binding motif protein 24 (ENSG00000287559).